banner

Board Member

bill fairey

Bill Fairey

Bill has twenty-eight years of experience in the bio-pharmaceutical industry working for both US and internationally based companies.

Currently, Bill is President of Actelion Pharmaceuticals US, a subsidiary of Actelion Pharmaceuticals, Europe’s largest Bio-pharmaceutical company. Since taking on the role in 2013, Bill has gained FDA approval and launched three significant products; OPSUMIT and UPTRAVI for PAH and VALCHLOR for MF-CTCL. The US organization has 400 employees and generated greater than $1 billion in net sales in 2015.

Prior to this role, he was VP Actelion’s Australia Asia Pacific and lived in Sydney Australia. As Regional VP, he focused on developing the company’s business across the Region through the founding of Actelion’s first affiliates in China, Taiwan, and Singapore, a the establishment of a distribution network across ASEAN, and ongoing oversight of the firm’s Australia/New Zealand affiliate. He served as Board Chair on the Actelion China Board. From 2003-2008, he was President of Actelion Canada, where he grew revenue and EBIT significantly over the five years in this role. He also served as a board member of Rx&D, the Canadian Pharmaceutical Manufacturers Association. Before promoted to the Canadian role, he worked for Actelion US and held the position of Vice President, Sales and Managed Markets. As one of the four original founding US management team members, his primary contributions included building the companies first sales force and managed markets divisions, establishing the market access strategy, distribution system and required operational support. Prior to Actelion US, Bill was with Parke-Davis Pharmaceuticals US for 12 years where he held a number of positions which included; Director, HealthCare Management, Business Director and multiple sales management roles. Therapeutic focus: CV, CNS, diabetes, and antibiotics.

He received his BS, in Biology from the University of Oregon (’87), his M.B.A. from Saint Mary’s College, California (’94) and currently reside in the Los Altos, California with his wife and two sons.

Actelion pharmaceuticals, Ltd, is a Swiss based biopharmaceutical company that focuses on the discovery, development and commercialization of innovative medicines. The company currently promotes four products worldwide, Tracleer (bosentan), Ventavis (iloprost) and Veletri (epoprostenol) for pulmonary hypertension and Zavesca (miglustat) for Type 1 Gaucher and NPC diseases.